RxDoctor Payments Data

Irene Semenov, DO

Neurology · Glenview, ILNPI 1093720856

Payments from drug & device makers

$1,512in general payments, 2019–2025

Across 29 payments — averaging $52.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$356
  • Amgen$218
  • Lundbeck LLC$207
  • Biohaven Pharmaceutical Holding Company Ltd.$200
  • Teva Pharmaceuticals USA, Inc.$194
  • Axsome Therapeutics, Inc.$121
  • plus $216 from 4 others

What the payments were for

  • Food & beverage$1,43195%
  • Education$805%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,512 in reported general payments places this provider in the 55th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$96,432
Medicare patients
471
Services billed
1,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant53$80,672
Nurtec OdtRimegepant Sulfate52$77,647
Aimovig AutoinjectorErenumab-Aooe60$58,656
Emgality PenGalcanezumab-Gnlm56$38,180
Gabapentin179$5,036
RizatriptanRizatriptan Benzoate65$1,761
Levetiracetam32$1,640
Diphenhydramine Hcl44$1,560
Phenobarbital19$948
Quetiapine Fumarate15$897
Amitriptyline Hcl44$873
Topiramate78$873
Pregabalin21$714
Eletriptan HbrEletriptan Hydrobromide12$672
Sumatriptan Succinate79$640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$356$80,67253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 790 neurology providers in Illinois.

Other neurology in Glenview

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →